39 results on '"Haixiang Shen"'
Search Results
2. SMAD3 and FTO are involved in miR-5581-3p-mediated inhibition of cell migration and proliferation in bladder cancer
- Author
-
Jiazhu Sun, Xueyou Ma, Yufan Ying, Weiyu Wang, Haixiang Shen, Song Wang, Haiyun Xie, Jiahe Yi, Weitao Zhan, Jiangfeng Li, and Ben Liu
- Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 ,Cytology ,QH573-671 - Abstract
Abstract Previous research evidence suggests that microRNAs (miRNAs) play an indispensable role in onset and progression of bladder cancer (BCa). Here, we explored the functions and mechanisms of miR-5581-3p in BCa. miR-5581-3p, as a tumor suppressor in BCa, was detected at a lower expression level in BCa tissue and cells in contrast with the non-malignant bladder tissue and cells. Over-expression of miR-5581-3p remarkably dampened the migration and proliferation of BCa in vitro and in vivo. SMAD3 and FTO were identified as the direct targets of miR-5581-3p by online databases prediction and mRNA-seq, which were further verified. SMAD3 as a star molecule in modulating EMT progress of BCa had been formulated in former studies. Meanwhile, FTO proved as an N6-methyladenosine (m6A) demethylase in decreasing m6A modification was confirmed to regulate the migration and proliferation in BCa. In addition, we conducted rescue experiments and confirmed overexpressing miR-5581-3p partially rescued the effects of the overexpressing SMAD3 and FTO in BCa cells. In conclusion, our studies exhibit that miR-5581-3p is a novel tumor inhibitor of BCa.
- Published
- 2022
- Full Text
- View/download PDF
3. Conditional survival of metastatic clear cell renal cell carcinoma: How prognosis evolves after cytoreductive surgery of primary tumor
- Author
-
Haixiang Shen, Jin Liu, Wei Liu, Jiazhu Sun, Xiangyi Zheng, Lisong Teng, Xiao Wang, and Liping Xie
- Subjects
clear cell ,conditional survival ,cytoreductive surgery ,metastatic renal cell carcinoma ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Introduction Cytoreductive surgery is one of the recommended treatments for metastatic renal cell carcinoma, while the prognostic information of these patients treated with cytoreductive surgery is limited. In this study, we aimed to investigate the survival profiles based on conditional survival (CS) estimates in metastatic clear cell renal cell carcinoma (mccRCC) patients treated with cytoreductive surgery of primary tumor. Methods and materials We identified and extracted mccRCC patients from the Surveillance, Epidemiology, and End Results database. We used Kaplan–Meier method to perform CS analyses. A multivariate Cox regression model was applied to explore the changes of well‐known prognostic factors. Results Conditional overall survival (COS) and conditional cancer‐specific survival (CCSS) improved increasingly at all periods of survivorships compared to survival estimates at baseline in overall population of mccRCC. The 36‐month COS improved by 3.3%–6.4% given per 12 additional months of survivorships and the CCSS improved significantly from 45.1% (95% CI 42.8–47.3) at 12 months to 67.1% (95% CI 62.0–71.7) at 60 months. Much more survival gain was observed in patients with advanced disease. Furthermore, the prognostic significance of age and pathological factors diminished and even disappeared in a long‐term survivorship. Conclusions Conditional overall survival and CCSS improved with time dynamically in mccRCC patients treated with cytoreductive surgery of primary tumor. Patients with advanced disease achieved significant survival gain and even could harvest a better prognosis given that the time of survivorship exceeds a certain period. Our findings could provide valuable and practical data for patient counseling and surveillance strategy making.
- Published
- 2021
- Full Text
- View/download PDF
4. circKDM4C enhances bladder cancer invasion and metastasis through miR-200bc-3p/ZEB1 axis
- Author
-
Xueyou Ma, Yufan Ying, Jiazhu Sun, Haiyun Xie, Jiangfeng Li, Liujia He, Weiyu Wang, Shiming Chen, Haixiang Shen, Jiahe Yi, Jindan Luo, Xiao Wang, Xiangyi Zheng, Ben Liu, and Liping Xie
- Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 ,Cytology ,QH573-671 - Abstract
Abstract Circular RNAs (circRNAs) play essential roles in human bladder cancer (BCa) development, however, unusual expression patterns and functional dysfunction of circRNAs in BCa have not been evaluated. In this study, we validated that circKDM4C (hsa_circ_0001839), derived from the KDM4C gene, is elevated in BCa cell lines as well as tissues. Functionally, overexpression of circKDM4C significantly enhances, and silencing of circKDM4C suppresses migration and invasion capabilities of BCa cells. Mechanistically, circKDM4C can directly interact with miR-200b-3p and miR-200c-3p as a miRNA sponge, which enhances the expression of ZEB1 and promotes mesenchymal phenotype. Conclusively, our findings indicate that circKDM4C may act as a pro-oncogenic factor in BCa invasion and metastasis via the circKDM4C/miR-200bc-3p/ZEB1 axis, which is a potential biomarker or therapeutic target for bladder cancer.
- Published
- 2021
- Full Text
- View/download PDF
5. MicroRNA‐501‐3p inhibits the proliferation of kidney cancer cells by targeting WTAP
- Author
-
Liujia He, Shiming Chen, Yufan Ying, Haiyun Xie, Jiangfeng Li, Xueyou Ma, Weiyu Wang, Haixiang Shen, Xiao Wang, Xiangyi Zheng, and Liping Xie
- Subjects
microRNA‐501‐3p ,proliferation ,renal cell carcinoma ,WTAP ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background Emerging evidence suggests that miR‐501‐3p plays an important role in the pathogenesis and progression of various carcinomas. However, its role and underlying mechanisms in renal cell carcinoma (RCC) remain to be elucidated. Methods Quantitative RT‐PCR, western blot, and bioinformatics methods were used to evaluate the expression of miR‐501‐3p and Wilms’ tumor 1‐associating protein (WTAP) in RCC cell lines and clinical tissues. The effects of miR‐501‐3p on the proliferation of RCC cells were investigated using flow cytometric, colony formation, and CCK8 assays. The target gene of miR‐501‐3p was confirmed by western blotting, qRT‐PCR, and dual‐luciferase reporter assays. The levels of RNA methylation with N6‐methyladenosine (m6A) following miR‐501‐3p overexpression or knockdown of its target gene were quantified using a dot‐blot assay. Results miR‐501‐3p expression was significantly downregulated in human RCC cell lines and tissues. In contrast, its overexpression markedly inhibited cancer cell proliferation in vitro by inducing G1 phase arrest. Moreover, WTAP was verified as a direct target gene of miR‐501‐3p. WTAP gene knockdown alone efficiently produced the same cancer‐inhibiting effects as miR‐501‐3p overexpression, with the level of m6A in RCC cells being decreased under both scenarios. The intermolecular interaction between miR‐501‐3p and WTAP was further substantiated by rescue experiments. Conclusion RCC progression is regulated via the miR‐501‐3p/WTAP/CDK2 axis and is inhibited by the overexpression of miR‐501‐3p.
- Published
- 2021
- Full Text
- View/download PDF
6. The prognostic value of lncRNA SNHG6 in cancer patients
- Author
-
Haixiang Shen, Qiwang Mo, Xin Xu, and Ben Liu
- Subjects
Cancer ,Prognosis ,Long no-coding RNA ,SNHG6 ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 ,Cytology ,QH573-671 - Abstract
Abstract Background Although tremendous improvement has been seen in cancer diagnosis and treatment, its morbidity and mortality is still high due to lack of ideal biomarkers. An increasing number of studies have demonstrated that the expression of lncRNA small nucleolar RNA host gene 6 (SNHG6) has significantly negative correlation with various cancer prognosis. The present meta-analysis was aimed to clarify the potential of clinical application of SNHG6 in cancers. Methods A detailed literature review was conducted by searching through PubMed and Web of Science databases. The expression level of SNHG6, clinicopathological features and survival outcomes were extracted from eligible studies. Pooled analysis was performed with a DerSimonian-Laird random-effect model. The results were further validated through the Cancer Genome Atlas (TCGA) dataset. Results Five studies with a total of 487 cases were finally included in this meta-analysis. The results demonstrated that a high expression of SNHG6 was significantly associated with an increased risk of poor overall survival (OS) in cancer patients (HR = 2.06, 95% CI 1.56–2.73). Similar results from the TCGA dataset further confirmed our findings. Conclusions Overexpressed SNHG6 was significantly associated with poor prognosis in various cancers. Therefore, SNHG6 may become a novel molecular target for treatment and prognostic evaluation.
- Published
- 2020
- Full Text
- View/download PDF
7. The characteristics of androgen receptor splice variant 7 in the treatment of hormonal sensitive prostate cancer: a systematic review and meta-analysis
- Author
-
Zhize Wang, Haixiang Shen, Zhen Liang, Yeqing Mao, Chaojun Wang, and Liping Xie
- Subjects
Androgen receptor splicing variant 7 ,First-line hormonal therapy ,Prostatectomy ,Prostate cancer ,Predictor ,Survival ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 ,Cytology ,QH573-671 - Abstract
Abstract Background Accumulating evidence suggests androgen receptor splice variant 7 (AR-V7) may be associated with the prognosis of castration-resistant prostate cancer (CRPC) received novel hormonal therapy while its characteristic and prognosis value in hormonal sensitive prostate cancer is unclear. Methods We aimed to evaluate the prognostic role of AR-V7 by progression free survival (PFS) and overall survival (OS) in hormonal sensitive prostate cancer (HSPC), and the AR-V7-positive-proportion difference in HSPC and CRPC. A search of PubMed, Embase, and the Web of Science was performed using the keywords prostate cancer, prostate tumor, prostate neoplasm, prostate carcinoma; AR-V7, AR3, androgen receptor splicing variant-7, or androgen receptor-3. Seventeen trials published due December 2019 were enrolled. Results AR-V7-positive proportion in CRPC was significantly larger than newly diagnosed prostate cancer (PCa) (odds ratio [OR] 7.06, 95% confidence interval [CI] 2.52–19.83, P
- Published
- 2020
- Full Text
- View/download PDF
8. Clinicopathological characteristics of androgen receptor splicing variant 7 (AR-V7) expression in patients with castration resistant prostate cancer: A systematic review and meta‐analysis
- Author
-
Qinchen Li, Zhize Wang, Jiahe Yi, Haixiang Shen, Zitong Yang, Libin Yan, and Liping Xie
- Subjects
Androgen receptor splicing variant 7 ,Clinicopathological characteristics ,Castration resistance prostate cancer ,TNM stage ,Meta – analysis ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Background: Studies have shown that AR-V7 may be correlated with the poor prognosis of castration resistant prostate cancer (CRPC), however, clinicopathological characteristics of AR-V7 have not been fully elucidated. Objective: This study aimed at evaluating the clinicopathological features of AR-V7 in CRPC patients. Materials and methods: To evaluate the clinicopathological features of AR-V7 in CRPC patients. A search of PubMed, Embase, and Web of Science was performed using the keywords prostate cancer, prostate tumor, prostate neoplasm, prostate carcinoma, AR-V7, AR3, androgen receptor splicing variant-7, or androgen receptor-3. Twenty-four trials published by February 2020 were included in this study. Results: The proportion of Gleason score ≥ 8 was found to be significantly higher in AR-V7-positive CRPC (69.5%) than negative (54.9%) (OR 1.68, 95% CI 1.25–2.25, p
- Published
- 2021
- Full Text
- View/download PDF
9. Comprehensive Analysis of Ferroptosis Regulators With Regard to PD-L1 and Immune Infiltration in Clear Cell Renal Cell Carcinoma
- Author
-
Song Wang, Shiming Chen, Yufan Ying, Xueyou Ma, Haixiang Shen, Jiangfeng Li, Xiao Wang, Yiwei Lin, Ben Liu, Xiangyi Zheng, and Liping Xie
- Subjects
ferroptosis ,clear cell renal cell carcinoma ,PD-L1 ,immune infiltration ,cars ,therapeutic target ,Biology (General) ,QH301-705.5 - Abstract
Clear cell renal cell carcinoma (ccRCC) is one of the tumor types with sensitivity to ferroptosis, and immunotherapy has emerged as a standard pillar for metastatic ccRCC treatment, while it remains largely obscure whether ferroptosis influences the tumor immune microenvironment in ccRCC. Based on available data in The Cancer Genome Atlas, divergent expression profiles of ferroptosis regulators were noted in ccRCC and normal tissues, and we also found that the ferroptosis regulators correlated with the PD-L1 expression. Two independent subtypes were determined by consensus clustering analysis according to the expression level of ferroptosis regulators in ccRCC. Cluster 1 showed lower histological tumor stage and grade, more favorable prognosis, and higher PD-L1 expression compared to cluster 2. CIBERSORT analysis revealed that cluster 2 harbored higher infiltrated levels of CD8+ T cell, Tregs, and T follicular helper cell, while cluster 1 more correlated with the monocyte, M1 macrophage, and M2 macrophage. Gene set enrichment analysis indicated that the ERBB signaling and JAK_STAT signaling pathways were significantly enriched in cluster 1. We subsequently identified CARS as the potentially key immune infiltration-related ferroptosis regulator, whose high expression showed dismal prognosis and was positively correlated with PD-L1 expression in ccRCC. We also verified the upregulation of CARS in ccRCC tissues and cell lines via qRT-PCR method. Additionally, a pan-cancer analysis demonstrated that CARS closely related to the expression of immune checkpoint-related genes (especially PD-L1) and an unfavorable prognosis in diverse cancer types. In summary, our study suggested the crucial role of ferroptosis in immune infiltration of ccRCC, and CARS is a potentially novel prognostic biomarker and potential target for cancer immunotherapy.
- Published
- 2021
- Full Text
- View/download PDF
10. Expression and Prognostic Value of Chromobox Family Proteins in Esophageal Cancer
- Author
-
Jin Liu, Haixiang Shen, Xiangliu Chen, Yongfeng Ding, Haiyong Wang, Nong Xu, and Lisong Teng
- Subjects
esophageal cancer (EC) ,Chromobox (CBX) ,biomarker ,Genetics ,QH426-470 - Abstract
Background: Esophageal cancer (EC) is one of the most common human malignant tumors worldwide. Chromobox (CBX) family proteins are significant components of epigenetic regulatory complexes. It is reported that CBXs play critical roles in the oncogenesis and development of various tumors. Nonetheless, their functions and specific roles in EC remain vague and obscure. Methods and Materials: We used multiple bioinformatics tools, including Oncomine, Gene Expression Profiling Interactive Analysis 2 (GEPIA2), UALCAN, Kaplan–Meier plotter, cBioPortal, Metascape, TIMER2 and TISIDB, to investigate the expression profile, gene alterations and prognostic roles of CBX family proteins, as well as their association with clinicopathologic parameters, immune cells and immune regulators. In addition, RT-qPCR, Western blot, CCK8, colony formation, wound healing and transwell assays were performed to investigate the biological functions of CBX3 in EC cells. Results: CBX3 and CBX5 were overexpressed in EC compared to normal tissues. Survival analysis revealed that high expression of CBX1 predicted worse disease-free survival (DFS) in EC patients. Functionally, CBXs might participate in mismatch repair, spliceosome, cell cycle, the Fanconi anemia pathway, tight junction, the mRNA surveillance pathway and the Hippo signaling pathway in EC development. Furthermore, CBXs were related to distinct immune cells infiltration and immune regulators. Additionally, depletion of CBX3 inhibited the proliferation, migration and invasion abilities of EC cells. Conclusions: Our study comprehensively investigated the expression pattern, prognostic value, and gene alterations of CBXs in EC, as well as their relationships with clinicopathologic variables, immune cells infiltration and immune regulators. These results suggested that CBX family proteins, especially CBX3, might be potential biomarkers in the progression of EC.
- Published
- 2022
- Full Text
- View/download PDF
11. Prognostic Value of Tumor-Associated Macrophages in Clear Cell Renal Cell Carcinoma: A Systematic Review and Meta-Analysis
- Author
-
Haixiang Shen, Jin Liu, Shiming Chen, Xueyou Ma, Yufan Ying, Jiangfeng Li, Weiyu Wang, Xiao Wang, and Liping Xie
- Subjects
tumor-associated macrophages ,clinicopathological significance ,survival ,clear cell renal cell carcinoma ,biomarker ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
BackgroundTumor-associated macrophages (TAMs) are the major immune cells in tumor microenvironment. The prognostic significance of TAMs has been confirmed in various tumors. However, whether TAMs can be prognostic factors in clear cell renal cell carcinoma (ccRCC) is unclear. In this study, we aimed to clarify the prognostic value of TAMs in ccRCC.MethodsWe searched PubMed, Embase, and the Web of Science for relevant published studies before December 19, 2020. Evidence from enrolled studies were pooled and analyzed by a meta-analysis. Hazard ratios (HRs) and odd ratios (ORs) with 95% confidence intervals (CIs) were computed to evaluate the pooled results.ResultsBoth of high CD68+ TAMs and M2-TAMs were risk factors for poor prognosis in ccRCC patients. The pooled HRs indicated that elevated CD68+ TAMs correlated with poor OS and PFS (HR: 3.97, 95% CI 1.39–11.39; HR: 5.73, 95% CI 2.36–13.90, respectively). For M2-TAMs, the pooled results showed ccRCC patients with high M2-TAMs suffered a worse OS and shorter PFS, with HR 1.32 (95% CI 1.16–1.50) and 1.40 (95% CI 1.14–1.72), respectively. Also, high density of TAMs was associated with advanced clinicopathological features in ccRCC.ConclusionsTAMs could be potential biomarkers for prognosis and novel targets for immunotherapy in ccRCC. Further researches are warranted to validate our results.
- Published
- 2021
- Full Text
- View/download PDF
12. The Prognostic Value of Androgen Receptor Splice Variant 7 in Castration-Resistant Prostate Cancer Treated With Novel Hormonal Therapy or Chemotherapy: A Systematic Review and Meta-analysis
- Author
-
Zhize Wang, Haixiang Shen, Nieying Ma, Qinchen Li, Yeqing Mao, Chaojun Wang, and Liping Xie
- Subjects
androgen receptor splicing variant 7 ,novel hormonal therapy ,chemotherapy ,prostate cancer ,predictor ,survival ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
PurposeThis study aimed to evaluate the prognostic role of AR-V7 in terms of prostate-specific antigen (PSA) response, progression-free survival (PFS), and overall survival (OS) in CRPC patients treated with novel hormonal therapy (NHT) (Abiraterone and Enzalutamide) or taxane-based chemotherapy (Docetaxel and Cabazitaxel).MethodsA comprehensive literature search was conducted on PubMed, Embase, and the Web of Science from inception to February 2020. Studies focusing on the prognostic values of AR-V7 in CRPC patients treated with NHT or chemotherapy were included in our meta-analysis. The OS and PFS were analyzed based on Hazard ratios (HRs) and 95% confidence intervals (CIs). Furthermore, Odds ratios (ORs) and 95% CIs were summarized for the AR-V7 conversion after treatment and the PSA response.ResultsThe AR-V7 positive proportion increased significantly after NHT treatment (OR 2.56, 95% CI 1.51–4.32, P
- Published
- 2020
- Full Text
- View/download PDF
13. Carbohydrates, Glycemic Index, and Glycemic Load in Relation to Bladder Cancer Risk
- Author
-
Hejia Zhu, Qiwang Mo, Haixiang Shen, Song Wang, Ben Liu, and Xin Xu
- Subjects
bladder cancer ,carbohydrates ,glycemic index ,glycemic load ,meta-analysis ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Objective: Epidemiologic studies investigating the association between dietary carbohydrates as well as glycemic index and glycemic load (markers of carbohydrate quality) and bladder cancer risk have yielded inconsistent results. The aim of the present meta-analysis is to summarize the evidence on this association.Materials and Methods: A comprehensive literature search of articles published by December 2019 was performed in PubMed, Scopus, and Web of Science databases. A random-effects model was used to calculate the pooled odds ratios (ORs) and their corresponding 95% confidence intervals (CIs).Results: Twelve observational studies were included in the final analysis. There was no evidence of an association between consumption of carbohydrates and bladder cancer risk (pooled OR, 1.04; 95% CI, 0.92–1.17). No statistically significant association between glycemic load and bladder cancer was likewise found (pooled OR, 1.10; 95% CI, 0.85–1.42). However, there was a significant positive association between glycemic index and bladder cancer risk (pooled OR, 1.25; 95% CI, 1.11–1.41). In the dose–response analysis, the pooled OR (95% CI) per 10 units of glycemic index per day was 1.02 (95% CI, 1.01–1.04).Conclusion: In this meta-analysis, glycemic index showed a positive linear association with bladder cancer risk.
- Published
- 2020
- Full Text
- View/download PDF
14. SP1/AKT/FOXO3 Signaling Is Involved in miR-362-3p-Mediated Inhibition of Cell-Cycle Pathway and EMT Progression in Renal Cell Carcinoma
- Author
-
Hejia Zhu, Song Wang, Haixiang Shen, Xiangyi Zheng, and Xin Xu
- Subjects
miR-362-3p ,SP1 ,FOXO3 ,renal cell carcinoma ,microRNA ,Biology (General) ,QH301-705.5 - Abstract
Emerging evidence has indicated that dysregulation of miR-362-3p is involved in the initiation and progression of several types of human cancers. However, the molecular mechanism of miR-362-3p in renal cell carcinoma (RCC) is still not completely clear. In this study, we found that miR-362-3p was frequently down-regulated in human RCC tissues. Overexpression of miR-362-3p in RCC cells significantly suppressed the proliferation, cell cycle and motility in vitro and in vivo via regulating AKT/FOXO3 signaling. We further confirmed that SP1 was a direct target of miR-362-3p. Knockdown of SP1 expression by a small interfering RNA (siRNA) phenocopied the effect of miR-362-3p overexpression in RCC cells. In conclusion, the current results provide evidence for the role of miR-362-3p in the pathogenesis of RCC and thus miR-362-3p may serve as an attractive candidate for RCC therapy.
- Published
- 2020
- Full Text
- View/download PDF
15. The influence of prostate volume on pathological outcomes after radical prostatectomy: A single-center retrospective study.
- Author
-
Qinchen Li, Zitong Yang, Zhize Wang, Jiazhu Sun, Chao Wen, Huaqing Yan, Haixiang Shen, Weiyu Wang, Bohan Xu, Jianjian Xiang, Xiaodong Teng, Cheng Zhang, Xiangyi Zheng, and Liping Xie
- Published
- 2023
- Full Text
- View/download PDF
16. Conditional survival of metastatic clear cell renal cell carcinoma: How prognosis evolves after cytoreductive surgery of primary tumor
- Author
-
Wei Liu, Lisong Teng, Xiao Wang, Xiangyi Zheng, Jiazhu Sun, Liping Xie, Haixiang Shen, and Jin Liu
- Subjects
Male ,Oncology ,Cancer Research ,medicine.medical_specialty ,Population ,Kaplan-Meier Estimate ,metastatic renal cell carcinoma ,clear cell ,Renal cell carcinoma ,Internal medicine ,Survivorship curve ,Epidemiology ,Humans ,Medicine ,cytoreductive surgery ,Radiology, Nuclear Medicine and imaging ,Neoplasm Metastasis ,education ,Carcinoma, Renal Cell ,Research Articles ,RC254-282 ,Aged ,Neoplasm Staging ,Proportional Hazards Models ,education.field_of_study ,conditional survival ,business.industry ,Proportional hazards model ,Clinical Cancer Research ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Cytoreduction Surgical Procedures ,Middle Aged ,Prognosis ,medicine.disease ,Primary tumor ,Kidney Neoplasms ,Clear cell renal cell carcinoma ,Female ,business ,Clear cell ,Research Article - Abstract
Introduction Cytoreductive surgery is one of the recommended treatments for metastatic renal cell carcinoma, while the prognostic information of these patients treated with cytoreductive surgery is limited. In this study, we aimed to investigate the survival profiles based on conditional survival (CS) estimates in metastatic clear cell renal cell carcinoma (mccRCC) patients treated with cytoreductive surgery of primary tumor. Methods and materials We identified and extracted mccRCC patients from the Surveillance, Epidemiology, and End Results database. We used Kaplan–Meier method to perform CS analyses. A multivariate Cox regression model was applied to explore the changes of well‐known prognostic factors. Results Conditional overall survival (COS) and conditional cancer‐specific survival (CCSS) improved increasingly at all periods of survivorships compared to survival estimates at baseline in overall population of mccRCC. The 36‐month COS improved by 3.3%–6.4% given per 12 additional months of survivorships and the CCSS improved significantly from 45.1% (95% CI 42.8–47.3) at 12 months to 67.1% (95% CI 62.0–71.7) at 60 months. Much more survival gain was observed in patients with advanced disease. Furthermore, the prognostic significance of age and pathological factors diminished and even disappeared in a long‐term survivorship. Conclusions Conditional overall survival and CCSS improved with time dynamically in mccRCC patients treated with cytoreductive surgery of primary tumor. Patients with advanced disease achieved significant survival gain and even could harvest a better prognosis given that the time of survivorship exceeds a certain period. Our findings could provide valuable and practical data for patient counseling and surveillance strategy making., In this study, we investigated the survival profiles based on conditional survival estimates in metastatic clear cell renal cell carcinoma (mccRCC) patients treated with cytoreductive surgery of primary tumor. We found that COS and CCSS improved with time dynamically in all mccRCC patients treated with cytoreductive surgery of primary tumor.
- Published
- 2021
17. MicroRNA‐501‐3p inhibits the proliferation of kidney cancer cells by targeting WTAP
- Author
-
Weiyu Wang, Jiangfeng Li, Xiangyi Zheng, Xiao Wang, Haixiang Shen, Xueyou Ma, Haiyun Xie, Liujia He, Liping Xie, Shiming Chen, and Yufan Ying
- Subjects
renal cell carcinoma ,Cancer Research ,proliferation ,Cell Cycle Proteins ,Transfection ,Pathogenesis ,Western blot ,Cell Line, Tumor ,microRNA ,medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,RC254-282 ,Research Articles ,Cell Proliferation ,Cancer Biology ,Gene knockdown ,biology ,medicine.diagnostic_test ,Cyclin-dependent kinase 2 ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Kidney Neoplasms ,In vitro ,WTAP ,Blot ,MicroRNAs ,Oncology ,Cell culture ,biology.protein ,Cancer research ,RNA Splicing Factors ,microRNA‐501‐3p ,Research Article - Abstract
Background Emerging evidence suggests that miR‐501‐3p plays an important role in the pathogenesis and progression of various carcinomas. However, its role and underlying mechanisms in renal cell carcinoma (RCC) remain to be elucidated. Methods Quantitative RT‐PCR, western blot, and bioinformatics methods were used to evaluate the expression of miR‐501‐3p and Wilms’ tumor 1‐associating protein (WTAP) in RCC cell lines and clinical tissues. The effects of miR‐501‐3p on the proliferation of RCC cells were investigated using flow cytometric, colony formation, and CCK8 assays. The target gene of miR‐501‐3p was confirmed by western blotting, qRT‐PCR, and dual‐luciferase reporter assays. The levels of RNA methylation with N6‐methyladenosine (m6A) following miR‐501‐3p overexpression or knockdown of its target gene were quantified using a dot‐blot assay. Results miR‐501‐3p expression was significantly downregulated in human RCC cell lines and tissues. In contrast, its overexpression markedly inhibited cancer cell proliferation in vitro by inducing G1 phase arrest. Moreover, WTAP was verified as a direct target gene of miR‐501‐3p. WTAP gene knockdown alone efficiently produced the same cancer‐inhibiting effects as miR‐501‐3p overexpression, with the level of m6A in RCC cells being decreased under both scenarios. The intermolecular interaction between miR‐501‐3p and WTAP was further substantiated by rescue experiments. Conclusion RCC progression is regulated via the miR‐501‐3p/WTAP/CDK2 axis and is inhibited by the overexpression of miR‐501‐3p., miR‐501‐3p was significantly down‐regulated in human RCC cell lines and tissues. Moreover, WTAP was confirmed as the direct target gene of miR‐501‐3p. RCC progression is regulated via the miR‐501‐3p/WTAP/CDK2 axis and is inhibited by the overexpression of the microRNA.
- Published
- 2021
18. miR-665 inhibits epithelial-to-mesenchymal transition in bladder cancer via the SMAD3/SNAIL axis
- Author
-
Shiming Chen, Liping Xie, Yufan Ying, Mingjie Xu, Xiao Wang, Ben Liu, Haixiang Shen, Haiyun Xie, Weiyu Wang, Jiangfeng Li, Liujia He, Xueyou Ma, and Xiangyi Zheng
- Subjects
Epithelial-Mesenchymal Transition ,Snail ,Biology ,Metastasis ,Cell Movement ,Cell Line, Tumor ,biology.animal ,Databases, Genetic ,microRNA ,medicine ,Humans ,Gene silencing ,Neoplasm Invasiveness ,Smad3 Protein ,Epithelial–mesenchymal transition ,Phosphorylation ,3' Untranslated Regions ,Molecular Biology ,Binding Sites ,Bladder cancer ,integumentary system ,Cancer ,Cell Biology ,Methylation ,medicine.disease ,Gene Expression Regulation, Neoplastic ,MicroRNAs ,Urinary Bladder Neoplasms ,Cancer research ,Snail Family Transcription Factors ,Research Paper ,Signal Transduction ,Developmental Biology - Abstract
Emerging research indicates that miRNAs can regulate cancer progression by influencing molecular pathways. Here, we studied miR-665, part of the DLK1-DIO3 miRNA cluster, which is downregulated by upstream methylation in bladder cancer. MiR-665 overexpression significantly downregulated the expression of SMAD3, phospho-SMAD3, and SNAIL, reversed epithelial-mesenchymal transition progression, and inhibited the migration of bladder cancer cells. To predict potential targets of miR-665, we used online databases and subsequently determined that miR-665 binds directly to the 3' untranslated region of SMAD3. Moreover, silencing of SMAD3 with small interfering RNAs phenocopied the effect of miR-665 overexpression, and overexpression of SMAD3 restored miR-665-overexpression-induced metastasis. This study revealed the role of the miR-665/SMAD3/SNAIL axis in bladder cancer, as well as the potential of miR-665 as a promising therapeutic target.
- Published
- 2021
19. The clinicopathological significance and prognostic value of programmed death-ligand 1 in prostate cancer: a meta-analysis of 3133 patients
- Author
-
Zhize Wang, Liping Xie, Guoliang Sun, Haixiang Shen, Qinchen Li, Libin Yan, and Jin Liu
- Subjects
PD-L1 ,Male ,Oncology ,Aging ,medicine.medical_specialty ,clinicopathological ,Cochrane Library ,B7-H1 Antigen ,Disease-Free Survival ,Prostate cancer ,Internal medicine ,Biomarkers, Tumor ,medicine ,Humans ,Aged ,Aged, 80 and over ,biology ,business.industry ,Hazard ratio ,Prostatic Neoplasms ,Cell Biology ,Odds ratio ,Publication bias ,DNA Methylation ,Middle Aged ,prostate cancer ,Prognosis ,medicine.disease ,Confidence interval ,meta-analysis ,Meta-analysis ,biology.protein ,Neoplasm Grading ,business ,Research Paper - Abstract
Background: Programmed death-ligand 1 (PD-L1) is considered an adverse factor predicting poor prognosis in various cancers, but the significance of PD-L1 expression for the prognosis of prostate cancer (PCa) is still unclear. We aimed to investigate the clinicopathological significance and prognostic value of PD-L1 expression in PCa. Methods: Studies were retrieved from PubMed, Web of Science, Cochrane Library and Embase before March 23, 2020. Odds ratios (ORs) and hazard ratios (HRs) with 95% confidence intervals (CIs) were obtained to assess the results. Begg’s test was applied to evaluate publication bias. Results: Fourteen studies involving 3133 cases were analyzed. The pooled data showed that both PD-L1 protein expression and PD-L1 DNA methylation (mPD-L1) were negatively associated with biochemical recurrence-free survival, with HRs of 1.67 (95% CI = 1.38-2.06, p < 0.001) and 2.23 (95% CI = 1.51-3.29, p < 0.001), respectively. In addition, PD-L1 overexpression was significantly related to advanced tumor stage (OR = 1.40, 95% CI= 1.13-1.75, p = 0.003), positive surgical margin (OR = 1.36, 95% CI = 1.03-1.78, p = 0.028), higher Gleason score (OR = 1.81, 95% CI = 1.35-2.42, p < 0.001) and androgen receptor positivity (OR = 2.20, 95% CI = 1.61-3.01, p < 0.001), while no significant correlation with age (p = 0.122), preoperative PSA (p = 0.796) or nodal status (p = 0.113) was observed. Conclusions: The study revealed that high expression of PD-L1 was related to unfavorable prognosis and advanced clinicopathological factors in PCa patients.
- Published
- 2020
20. The Impact of Prostate Volume on Pathological Outcome after Radical Prostatectomy: A Single-Center Retrospective Study
- Author
-
Qinchen Li, Zitong Yang, Zhize Wang, Jiazhu Sun, Chao Wen, Huaqing Yan, Haixiang Shen, Weiyu Wang, Bohan Xu, Jianjian Xiang, Xiaodong Teng, Cheng Zhang, Xiangyi Zheng, and Li-Ping Xie
- Published
- 2022
21. Reproductive and hormonal factors and bladder cancer risk: a prospective study and meta-analysis
- Author
-
Song Wang, Xin Xu, Ben Liu, Haixiang Shen, and Qiwang Mo
- Subjects
Oncology ,Aging ,medicine.medical_specialty ,PLCO ,Risk Assessment ,Cohort Studies ,Risk Factors ,Prostate ,Internal medicine ,medicine ,Humans ,Prospective Studies ,Age of Onset ,Prospective cohort study ,Bladder cancer ,hormones ,business.industry ,Reproduction ,Cell Biology ,Middle Aged ,medicine.disease ,United States ,meta-analysis ,Menopause ,Parity ,medicine.anatomical_structure ,Urinary Bladder Neoplasms ,Meta-analysis ,Cohort ,bladder cancer ,Female ,reproductive factors ,business ,Research Paper ,Cohort study ,Hormone - Abstract
Bladder cancer is three to four times more common among men than women. The objectives of this study were to explore the association between reproductive and hormonal factors and risk of bladder cancer among women using data from the Prostate, Lung, Colorectal and Ovarian (PLCO) cohort, and to perform a meta-analysis based on cohort studies. After a median of 11.6 years of follow-up, 237 incident bladder cancer cases were identified in PLCO cohort. Compared with menopause at 50-54 years, earlier menopause (< 45 years) was positively but not significantly associated with bladder cancer risk (HR 1.25, 95% CI 0.91-1.71; p = 0.176). In the meta-analysis, parous women had significantly lower bladder cancer risk than nulliparous women (pooled HR 0.79, 95% CI 0.73-0.86). In addition, menopause at an earlier age was significantly associated with a higher risk of bladder cancer (pooled HR 1.22, 95% CI 1.06-1.40). In conclusion, this study indicated a greater risk in bladder cancer among nulliparous women and among women with early menopause. Further studies are needed to understand the underlying mechanisms.
- Published
- 2020
22. Primary Prostatic Extra-Gastrointestinal Stromal Tumor Treated with Imatinib Mesylate as Neoadjuvant and Adjuvant Therapy: A Case Report and Literature Review
- Author
-
Xiao Wang, Zhize Wang, Haixiang Shen, Meibao Feng, Jin Liu, Jiangfeng Li, and Xin Xu
- Subjects
0301 basic medicine ,medicine.medical_specialty ,EGIST ,Urology ,Rectum ,Case Report ,Metastasis ,03 medical and health sciences ,extra-gastrointestinal stromal tumor ,0302 clinical medicine ,Prostate ,imatinib mesylate ,Adjuvant therapy ,Medicine ,Pharmacology (medical) ,Stromal tumor ,prostate ,GiST ,business.industry ,Urinary retention ,medicine.disease ,030104 developmental biology ,medicine.anatomical_structure ,Imatinib mesylate ,Oncology ,030220 oncology & carcinogenesis ,medicine.symptom ,business - Abstract
The current study presents a case of primary prostatic extra-gastrointestinal stromal tumor (EGIST) in a 43-year-old man who suffered acute urinary retention. The serum level of prostate-specific antigen was normal. Imaging examinations demonstrated a diffusely enlarged prostate compressing the rectum without evidence of metastasis. After excluding the possibility of secondary involvement by a rectal GIST, the pathologic diagnosis of primary prostatic EGIST was established based on microscopic study, immunohistochemistry, and molecular analysis. This patient is the first case with primary EGISTs of prostate received imatinib mesylate as neoadjuvant and adjuvant therapy reported in the literature to date. We hope this case could provide the experience of diagnosis and treatment of primary prostatic EGISTs.
- Published
- 2019
23. SMAD3 and FTO are involved in miR-5581-3p-mediated inhibition of cell migration and proliferation in bladder cancer
- Author
-
Jiazhu Sun, Xueyou Ma, Yufan Ying, Weiyu Wang, Haixiang Shen, Song Wang, Haiyun Xie, Jiahe Yi, Weitao Zhan, Jiangfeng Li, and Ben Liu
- Subjects
Cancer Research ,Cellular and Molecular Neuroscience ,Immunology ,Cell Biology ,skin and connective tissue diseases - Abstract
Previous research evidence suggests that microRNAs (miRNAs) play an indispensable role in onset and progression of bladder cancer (BCa). Here, we explored the functions and mechanisms of miR-5581-3p in BCa. miR-5581-3p, as a tumor suppressor in BCa, was detected at a lower expression level in BCa tissue and cells in contrast with the non-malignant bladder tissue and cells. Over-expression of miR-5581-3p remarkably dampened the migration and proliferation of BCa in vitro and in vivo. SMAD3 and FTO were identified as the direct targets of miR-5581-3p by online databases prediction and mRNA-seq, which were further verified. SMAD3 as a star molecule in modulating EMT progress of BCa had been formulated in former studies. Meanwhile, FTO proved as an N6-methyladenosine (m6A) demethylase in decreasing m6A modification was confirmed to regulate the migration and proliferation in BCa. In addition, we conducted rescue experiments and confirmed overexpressing miR-5581-3p partially rescued the effects of the overexpressing SMAD3 and FTO in BCa cells. In conclusion, our studies exhibit that miR-5581-3p is a novel tumor inhibitor of BCa.
- Published
- 2021
24. circKDM4C enhances bladder cancer invasion and metastasis through miR-200bc-3p/ZEB1 axis
- Author
-
Ben Liu, Liping Xie, Haiyun Xie, Xueyou Ma, Jiangfeng Li, Shiming Chen, Jiahe Yi, Weiyu Wang, Jindan Luo, Liujia He, Yufan Ying, Haixiang Shen, Jiazhu Sun, Xiangyi Zheng, and Xiao Wang
- Subjects
Cancer Research ,Bladder cancer ,QH573-671 ,Immunology ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Cancer ,Cell Biology ,Biology ,Epithelial-mesenchymal transition ,medicine.disease ,Phenotype ,Article ,Cell invasion ,Metastasis ,Cellular and Molecular Neuroscience ,Cell culture ,Potential biomarkers ,medicine ,Cancer research ,Gene silencing ,Cytology ,skin and connective tissue diseases ,Gene ,RC254-282 - Abstract
Circular RNAs (circRNAs) play essential roles in human bladder cancer (BCa) development, however, unusual expression patterns and functional dysfunction of circRNAs in BCa have not been evaluated. In this study, we validated that circKDM4C (hsa_circ_0001839), derived from the KDM4C gene, is elevated in BCa cell lines as well as tissues. Functionally, overexpression of circKDM4C significantly enhances, and silencing of circKDM4C suppresses migration and invasion capabilities of BCa cells. Mechanistically, circKDM4C can directly interact with miR-200b-3p and miR-200c-3p as a miRNA sponge, which enhances the expression of ZEB1 and promotes mesenchymal phenotype. Conclusively, our findings indicate that circKDM4C may act as a pro-oncogenic factor in BCa invasion and metastasis via the circKDM4C/miR-200bc-3p/ZEB1 axis, which is a potential biomarker or therapeutic target for bladder cancer.
- Published
- 2021
25. Clinicopathological characteristics of androgen receptor splicing variant 7 (AR-V7) expression in patients with castration resistant prostate cancer: A systematic review and meta‐analysis
- Author
-
Libin Yan, Zitong Yang, Qinchen Li, Liping Xie, Haixiang Shen, Zhize Wang, and Jiahe Yi
- Subjects
CRPC, castration resistance prostate cancer ,0301 basic medicine ,Oncology ,OR, odds radio ,Cancer Research ,medicine.medical_specialty ,medicine.drug_class ,M, metastasis ,Castration resistance prostate cancer ,HSPC, Hormone sensitive prostate cancer ,urologic and male genital diseases ,Metastasis ,03 medical and health sciences ,Prostate cancer ,Clinicopathological characteristics ,0302 clinical medicine ,Prostate ,Internal medicine ,medicine ,AR-V7, androgen receptor splicing variant 7 ,Stage (cooking) ,Androgen receptor splicing variant 7 ,ECGO, Eastern Cooperative Oncology Group ,RC254-282 ,Original Research ,N, node ,TNM stage ,PSA, Prostate specific antigen ,business.industry ,Bone metastasis ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,T, tumor ,Androgen ,medicine.disease ,Androgen receptor ,PRISMA, preferred reporting items for systematic reviews and meta-analyses ,Meta – analysis ,030104 developmental biology ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,AR, androgen receptor ,Prostate neoplasm ,business ,mCRPC, metastatic castration-resistant prostate cancer - Abstract
Highlights • Studies have shown that AR-V7 may be correlated with the poor prognosis of castration resistant prostate cancer (CRPC), however, clinicopathological characteristics of AR-V7 have not been fully elucidated. • We enrolled 24 studies with 2307 eligible patients for a systemic review and meta-analysis. • AR-V7 positivity was associated with higher Gleason score, bone or any site metastasis, presence of pain and worse ECOG performance score in CRPC. • Therefore, AR-V7 positivity may be a particular type of prostate cancer subtype in CRPC., Background Studies have shown that AR-V7 may be correlated with the poor prognosis of castration resistant prostate cancer (CRPC), however, clinicopathological characteristics of AR-V7 have not been fully elucidated. Objective This study aimed at evaluating the clinicopathological features of AR-V7 in CRPC patients. Materials and methods To evaluate the clinicopathological features of AR-V7 in CRPC patients. A search of PubMed, Embase, and Web of Science was performed using the keywords prostate cancer, prostate tumor, prostate neoplasm, prostate carcinoma, AR-V7, AR3, androgen receptor splicing variant-7, or androgen receptor-3. Twenty-four trials published by February 2020 were included in this study. Results The proportion of Gleason score ≥ 8 was found to be significantly higher in AR-V7-positive CRPC (69.5%) than negative (54.9%) (OR 1.68, 95% CI 1.25–2.25, p
- Published
- 2021
26. Comprehensive Analysis of Ferroptosis Regulators With Regard to PD-L1 and Immune Infiltration in Clear Cell Renal Cell Carcinoma
- Author
-
Liping Xie, Xiao Wang, Shiming Chen, Yiwei Lin, Jiangfeng Li, Xueyou Ma, Yufan Ying, Ben Liu, Haixiang Shen, Song Wang, and Xiangyi Zheng
- Subjects
0301 basic medicine ,PD-L1 ,QH301-705.5 ,medicine.medical_treatment ,T cell ,Cell ,Biology ,clear cell renal cell carcinoma ,Cell and Developmental Biology ,03 medical and health sciences ,0302 clinical medicine ,Cancer immunotherapy ,ErbB ,medicine ,Biology (General) ,Original Research ,immune infiltration ,Cancer ,cars ,therapeutic target ,Cell Biology ,Immunotherapy ,medicine.disease ,ferroptosis ,Clear cell renal cell carcinoma ,030104 developmental biology ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,Cancer research ,biology.protein ,Developmental Biology - Abstract
Clear cell renal cell carcinoma (ccRCC) is one of the tumor types with sensitivity to ferroptosis, and immunotherapy has emerged as a standard pillar for metastatic ccRCC treatment, while it remains largely obscure whether ferroptosis influences the tumor immune microenvironment in ccRCC. Based on available data in The Cancer Genome Atlas, divergent expression profiles of ferroptosis regulators were noted in ccRCC and normal tissues, and we also found that the ferroptosis regulators correlated with the PD-L1 expression. Two independent subtypes were determined by consensus clustering analysis according to the expression level of ferroptosis regulators in ccRCC. Cluster 1 showed lower histological tumor stage and grade, more favorable prognosis, and higher PD-L1 expression compared to cluster 2. CIBERSORT analysis revealed that cluster 2 harbored higher infiltrated levels of CD8+ T cell, Tregs, and T follicular helper cell, while cluster 1 more correlated with the monocyte, M1 macrophage, and M2 macrophage. Gene set enrichment analysis indicated that the ERBB signaling and JAK_STAT signaling pathways were significantly enriched in cluster 1. We subsequently identified CARS as the potentially key immune infiltration-related ferroptosis regulator, whose high expression showed dismal prognosis and was positively correlated with PD-L1 expression in ccRCC. We also verified the upregulation of CARS in ccRCC tissues and cell lines via qRT-PCR method. Additionally, a pan-cancer analysis demonstrated that CARS closely related to the expression of immune checkpoint-related genes (especially PD-L1) and an unfavorable prognosis in diverse cancer types. In summary, our study suggested the crucial role of ferroptosis in immune infiltration of ccRCC, and CARS is a potentially novel prognostic biomarker and potential target for cancer immunotherapy.
- Published
- 2021
27. Prognostic Value of Tumor-Associated Macrophages in Clear Cell Renal Cell Carcinoma: A Systematic Review and Meta-Analysis
- Author
-
Liping Xie, Xiao Wang, Yufan Ying, Jin Liu, Xueyou Ma, Shiming Chen, Jiangfeng Li, Weiyu Wang, and Haixiang Shen
- Subjects
0301 basic medicine ,Oncology ,Cancer Research ,medicine.medical_specialty ,medicine.medical_treatment ,Review ,clear cell renal cell carcinoma ,survival ,03 medical and health sciences ,0302 clinical medicine ,stomatognathic system ,Internal medicine ,medicine ,clinicopathological significance ,skin and connective tissue diseases ,RC254-282 ,Tumor microenvironment ,business.industry ,CD68 ,tumor-associated macrophages ,Hazard ratio ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Immunotherapy ,medicine.disease ,Confidence interval ,Clear cell renal cell carcinoma ,030104 developmental biology ,030220 oncology & carcinogenesis ,Meta-analysis ,Biomarker (medicine) ,biomarker ,business ,hormones, hormone substitutes, and hormone antagonists - Abstract
BackgroundTumor-associated macrophages (TAMs) are the major immune cells in tumor microenvironment. The prognostic significance of TAMs has been confirmed in various tumors. However, whether TAMs can be prognostic factors in clear cell renal cell carcinoma (ccRCC) is unclear. In this study, we aimed to clarify the prognostic value of TAMs in ccRCC.MethodsWe searched PubMed, Embase, and the Web of Science for relevant published studies before December 19, 2020. Evidence from enrolled studies were pooled and analyzed by a meta-analysis. Hazard ratios (HRs) and odd ratios (ORs) with 95% confidence intervals (CIs) were computed to evaluate the pooled results.ResultsBoth of high CD68+ TAMs and M2-TAMs were risk factors for poor prognosis in ccRCC patients. The pooled HRs indicated that elevated CD68+ TAMs correlated with poor OS and PFS (HR: 3.97, 95% CI 1.39–11.39; HR: 5.73, 95% CI 2.36–13.90, respectively). For M2-TAMs, the pooled results showed ccRCC patients with high M2-TAMs suffered a worse OS and shorter PFS, with HR 1.32 (95% CI 1.16–1.50) and 1.40 (95% CI 1.14–1.72), respectively. Also, high density of TAMs was associated with advanced clinicopathological features in ccRCC.ConclusionsTAMs could be potential biomarkers for prognosis and novel targets for immunotherapy in ccRCC. Further researches are warranted to validate our results.
- Published
- 2021
28. Dysregulation of ncRNAs located at the DLK1‑DIO3 imprinted domain: involvement in urological cancers
- Author
-
Xiao Wang, Huaqing Yan, Xin Xu, Liping Xie, Haixiang Shen, Song Wang, Jiangfeng Li, Mingjie Xu, Ke Jin, Yufan Ying, and Haiyun Xie
- Subjects
0301 basic medicine ,MEG3 ,DMRs ,epigenetics ,ncRNAs ,Computational biology ,Review ,Biology ,Non-coding RNA ,regulatory network ,03 medical and health sciences ,030104 developmental biology ,0302 clinical medicine ,Differentially methylated regions ,Oncology ,030220 oncology & carcinogenesis ,microRNA ,DLK1-DIO3 imprinted domain ,Epigenetics ,Small nucleolar RNA ,Genomic imprinting ,urological cancers ,Gene - Abstract
Genomic imprinting has been found to be involved in human physical development and several diseases. The DLK1-DIO3 imprinted domain is located on human chromosome 14 and contains paternally expressed protein-coding genes (DLK1, RTL1, DIO3) and numerous maternally expressed ncRNA genes (MEG3, MEG8, antisense RTL1, miRNAs, piRNAs, and snoRNAs). Emerging evidence has implicated that dysregulation of the DLK1-DIO3 imprinted domain especially the imprinted ncRNAs is critical for tumor progressions. Multiple miRNAs and lncRNAs have been investigated in urological cancers, of which several are transcribed from this domain. In this review, we present current data about the associated miRNAs, lncRNAs, and piRNAs and the regulation of differentially methylated regions methylation status in the progression of urological cancers and preliminarily propose certain concepts about the potential regulatory networks involved in DLK1-DIO3 imprinted domain.
- Published
- 2019
29. Effects of fluorescent light cystoscopy in non-muscle-invasive bladder cancer: A systematic review and meta-analysis
- Author
-
Jiazhu Sun, Ben Liu, Xueyou Ma, and Haixiang Shen
- Subjects
medicine.medical_specialty ,China ,030303 biophysics ,Biophysics ,Urology ,Dermatology ,Cochrane Library ,030207 dermatology & venereal diseases ,03 medical and health sciences ,0302 clinical medicine ,Fluorescent light ,Medicine ,Humans ,Pharmacology (medical) ,0303 health sciences ,Bladder cancer ,Photosensitizing Agents ,medicine.diagnostic_test ,business.industry ,Carcinoma in situ ,Cystoscopy ,Aminolevulinic Acid ,medicine.disease ,Confidence interval ,Oncology ,Photochemotherapy ,Urinary Bladder Neoplasms ,Meta-analysis ,Relative risk ,Neoplasm Recurrence, Local ,business - Abstract
The benefits of fluorescent light (FL) cystoscopy with 5-aminolevulinic acid (5-ALA) or hexaminolevulinate (HAL) in non-muscle-invasive bladder cancer (NMIBC) have been mentioned in many trials. Meanwhile, several problems need to be addressed such as the rate of residual disease following these procedures.To assess the effects of FL cystoscopy compared with white light (WL) cystoscopy on the rate of residual Ta, T1, and carcinoma in situ (CIS) tumors, recurrence-free survival (RFS) and progression-free survival (PFS).A search in the databases PubMed, Embase, the Cochrane Library, China National Knowledge Infrastructure (CNKI) and China Biology Medicine (CBM) was undertaken. Studies were included if their outcomes included the residual tumor rate, PFS or RFS. The data was analyzed by REVMAN 5.3 and STATA 14.0.The residual tumor rate of the FL group was lower than that of the WL group (relative risk [RR] 0.42; 95 % confidence interval [CI] 0.26-0.80; P = 0.007), which was consistent with the residual Ta rate (RR 0.44; 95 % CI 0.28-0.69; P = 0.0004), the residual T1 rate (RR 0.42; 95 % CI 0.21-0.83; P = 0.01) and the residual CIS rate (RR 0.39; 95 % CI 0.19-0.80; P = 0.01). RFS at the 12-month follow-up (RR 1.15; 95 % CI 1.08-1.28; P = 0.0002) and 24-month follow-up (RR 1.26; 95 % CI 1.17-1.35; P 0.00001) in the FL group was significantly higher than that in the WL group. However, no statistically significant differences were found in PFS at the 12-month follow-up (RR 1.01; 95 % CI 0.99-1.03; P = 0.17) or 24-month follow-up (RR 1.00; 95 % CI 0.97-1.03; P = 0.95).FL cystoscopy was related to a reduced residual tumor rate compared with WL cystoscopy in NMIBC, which was also consistent with the Ta, T1 and residual CIS rates. RFS was higher in patients with FL cystoscopy at the 12- to 24-month follow-up.
- Published
- 2021
30. FTO promotes clear cell renal cell carcinoma progression via upregulation of PDK1 through an m6 A dependent pathway.
- Author
-
Haixiang Shen, Yufan Ying, Xueyou Ma, Haiyun Xie, Shiming Chen, Jiazhu Sun, Zixiang Liu, Chao Wen, Zitong Yang, Xiao Wang, Mingjie Xu, Jindan Luo, Ben Liu, Jiangfeng Li, Xiangyi Zheng, and Liping Xie
- Published
- 2022
- Full Text
- View/download PDF
31. The Prognostic Value of Androgen Receptor Splice Variant 7 in Castration-Resistant Prostate Cancer Treated With Novel Hormonal Therapy or Chemotherapy: A Systematic Review and Meta-analysis
- Author
-
Liping Xie, Zhize Wang, Qinchen Li, Yeqing Mao, Haixiang Shen, Chaojun Wang, and Nieying Ma
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,medicine.medical_treatment ,predictor ,chemotherapy ,survival ,lcsh:RC254-282 ,chemistry.chemical_compound ,Prostate cancer ,Internal medicine ,medicine ,androgen receptor splicing variant 7 ,Enzalutamide ,novel hormonal therapy ,Chemotherapy ,Taxane ,business.industry ,Hazard ratio ,medicine.disease ,prostate cancer ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Docetaxel ,chemistry ,Cabazitaxel ,Hormonal therapy ,Systematic Review ,business ,medicine.drug - Abstract
PurposeThis study aimed to evaluate the prognostic role of AR-V7 in terms of prostate-specific antigen (PSA) response, progression-free survival (PFS), and overall survival (OS) in CRPC patients treated with novel hormonal therapy (NHT) (Abiraterone and Enzalutamide) or taxane-based chemotherapy (Docetaxel and Cabazitaxel).MethodsA comprehensive literature search was conducted on PubMed, Embase, and the Web of Science from inception to February 2020. Studies focusing on the prognostic values of AR-V7 in CRPC patients treated with NHT or chemotherapy were included in our meta-analysis. The OS and PFS were analyzed based on Hazard ratios (HRs) and 95% confidence intervals (CIs). Furthermore, Odds ratios (ORs) and 95% CIs were summarized for the AR-V7 conversion after treatment and the PSA response.ResultsThe AR-V7 positive proportion increased significantly after NHT treatment (OR 2.56, 95% CI 1.51–4.32, PConclusionNHT treatment increased AR-V7 positive proportion whereas chemotherapy decreased it. Moreover, AR-V7 positivity correlated with lower PSA response, poorer PFS, and OS in CRPC treated with NHT, and shorter OS in patients receiving chemotherapy.
- Published
- 2020
32. The Clinicopathological Characteristics of Androgen Receptor Splicing Variant 7 (AR-V7) Expression in Patients with Castration Resistance Prostate Cancer: A Systematic Review and Meta‐Analysis
- Author
-
Zhize Wang, Qinchen Li, Haixiang Shen, Chaojun Wang, and Liping Xie
- Abstract
BACKGROUND Accumulating studies indicate AR-V7 may be related to the poor prognosis of castration resistance prostate cancer (CRPC), while the evidence of the clinicopathological characteristics of AR-V7 is rare. METHODS To evaluate the clinicopathological features of AR-V7 in CRPC patients. A search of PubMed, Embase, and the Web of Science was performed using the keywords prostate cancer, prostate tumor, prostate neoplasm, prostate carcinoma; AR-V7, AR3, androgen receptor splicing variant-7, or androgen receptor-3. Twenty-four trials published due February 2020 were enrolled. RESULTS The proportion of Gleason score ≥ 8 was significantly higher in AR-V7-positive CRPC (69.5%) than negative (54.9%) (OR 1.68, 95% CI 1.25–2.25, PCONCLUSIONS AR-V7 positivity was associated with higher Gleason score, bone or any site metastasis, presence of pain and worse ECOG performance score in CRPC, but not related to tumor stage or lymph node metastasis. More studies are needed to confirm these findings.
- Published
- 2020
33. SP1/AKT/FOXO3 Signaling Is Involved in miR-362-3p-Mediated Inhibition of Cell-Cycle Pathway and EMT Progression in Renal Cell Carcinoma
- Author
-
Song Wang, Hejia Zhu, Xiangyi Zheng, Haixiang Shen, and Xin Xu
- Subjects
0301 basic medicine ,Small interfering RNA ,renal cell carcinoma ,Cell Cycle Pathway ,Biology ,urologic and male genital diseases ,03 medical and health sciences ,Cell and Developmental Biology ,0302 clinical medicine ,Renal cell carcinoma ,microRNA ,medicine ,lcsh:QH301-705.5 ,Protein kinase B ,Original Research ,Gene knockdown ,FOXO3 ,Cell Biology ,Cell cycle ,medicine.disease ,female genital diseases and pregnancy complications ,SP1 ,030104 developmental biology ,lcsh:Biology (General) ,030220 oncology & carcinogenesis ,Cancer research ,miR-362-3p ,Developmental Biology - Abstract
Emerging evidence has indicated that dysregulation of miR-362-3p is involved in the initiation and progression of several types of human cancers. However, the molecular mechanism of miR-362-3p in renal cell carcinoma (RCC) is still not completely clear. In this study, we found that miR-362-3p was frequently down-regulated in human RCC tissues. Overexpression of miR-362-3p in RCC cells significantly suppressed the proliferation, cell cycle and motility in vitro and in vivo via regulating AKT/FOXO3 signaling. We further confirmed that SP1 was a direct target of miR-362-3p. Knockdown of SP1 expression by a small interfering RNA (siRNA) phenocopied the effect of miR-362-3p overexpression in RCC cells. In conclusion, the current results provide evidence for the role of miR-362-3p in the pathogenesis of RCC and thus miR-362-3p may serve as an attractive candidate for RCC therapy.
- Published
- 2020
34. The utilization status of neoadjuvant chemotherapy in muscle-invasive bladder cancer: a systematic review and meta-analysis
- Author
-
Wei LIU, Jinhui TIAN, Su ZHANG, Enguang YANG, Haixiang SHEN, Fudong LI, Kailing LI, Tao ZHANG, Hanzhang WANG, Robert S. SVATEK, Ronald RODRIGUEZ, and Zhiping WANG
- Subjects
Models, Statistical ,Urology ,Antineoplastic Agents ,Cystectomy ,Global Health ,Neoadjuvant Therapy ,Urinary Bladder Neoplasms ,Nephrology ,Chemotherapy, Adjuvant ,Practice Guidelines as Topic ,Humans ,Neoplasm Invasiveness ,Guideline Adherence ,Practice Patterns, Physicians' - Abstract
To give a comprehensive depiction of the utilization status of neoadjuvant chemotherapy (NAC) in muscle invasive bladder cancer (MIBC) worldwide.Potential relevant research papers of Pubmed, Embase, Web of Science, and the Cochrane Library were reviewed to identify eligible studies. Primary outcomes of this meta-analysis were utilization rate of NAC and its utility distribution in different genders, races, ages, countries and temporal trends. The utilization rates of NAC were calculated as 'Proportion (s)' with 95% confidence intervals (CIs) and pooled estimates were calculated by using a random-effect model.A total of thirteen studies and 35,738 patients were included. The total proportion of NAC applied in MIBC populations prior to radical cystectomy (RC) was 17.2% (95% CI: 12.5-21.9%, IThe present study shows the low utilization rate of NAC in MIBC patients. Standardization of the treatment modality of MIBC and promotion of guidelines might be necessary to expedite the adoption of NAC in near future.
- Published
- 2020
35. Additional file 1 of The characteristics of androgen receptor splice variant 7 in the treatment of hormonal sensitive prostate cancer: a systematic review and meta-analysis
- Author
-
Wang, Zhize, Haixiang Shen, Liang, Zhen, Yeqing Mao, Chaojun Wang, and Liping Xie
- Abstract
Additional file 1: Figure S1. The funnel plot for meta-analysis of the AR-V7 positive proportion in newly diagnosis prostate cancer and CRPC. Figure S2. The funnel plot for meta-analysis of the progression free survival of first-line hormonal therapy in HSPC of different AR-V7 status. Figure S3. The funnel plot for meta-analysis of the overall survival of first-line hormonal therapy in HSPC of different AR-V7 status. Table S1. Target specimens and AR-V7 detection assay of studies in the positive proportion meta-analysis in newly diagnosed PCa and CRPC. Table S2. Definition of PSA response, PFS and OS in the studies included in the meta-analysis of prognosis for hormonal therapy and chemotherapy in different AR-V7 states.
- Published
- 2020
- Full Text
- View/download PDF
36. The prognostic value of lncRNA SNHG6 in cancer patients
- Author
-
Xin Xu, Qiwang Mo, Ben Liu, and Haixiang Shen
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,Poor prognosis ,Host gene ,Review ,lcsh:RC254-282 ,Cancer prognosis ,03 medical and health sciences ,0302 clinical medicine ,Cancer genome ,Internal medicine ,Genetics ,Overall survival ,medicine ,SNHG6 ,lcsh:QH573-671 ,030304 developmental biology ,Cancer ,0303 health sciences ,business.industry ,lcsh:Cytology ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Prognosis ,Long no-coding RNA ,Increased risk ,Pooled analysis ,030220 oncology & carcinogenesis ,Molecular targets ,business - Abstract
Background Although tremendous improvement has been seen in cancer diagnosis and treatment, its morbidity and mortality is still high due to lack of ideal biomarkers. An increasing number of studies have demonstrated that the expression of lncRNA small nucleolar RNA host gene 6 (SNHG6) has significantly negative correlation with various cancer prognosis. The present meta-analysis was aimed to clarify the potential of clinical application of SNHG6 in cancers. Methods A detailed literature review was conducted by searching through PubMed and Web of Science databases. The expression level of SNHG6, clinicopathological features and survival outcomes were extracted from eligible studies. Pooled analysis was performed with a DerSimonian-Laird random-effect model. The results were further validated through the Cancer Genome Atlas (TCGA) dataset. Results Five studies with a total of 487 cases were finally included in this meta-analysis. The results demonstrated that a high expression of SNHG6 was significantly associated with an increased risk of poor overall survival (OS) in cancer patients (HR = 2.06, 95% CI 1.56–2.73). Similar results from the TCGA dataset further confirmed our findings. Conclusions Overexpressed SNHG6 was significantly associated with poor prognosis in various cancers. Therefore, SNHG6 may become a novel molecular target for treatment and prognostic evaluation.
- Published
- 2019
37. The utilization status of neoadjuvant chemotherapy in muscle-invasive bladder cancer: a systematic review and meta-analysis.
- Author
-
Wei LIU, Jinhui TIAN, Su ZHANG, Enguang YANG, Haixiang SHEN, Fudong LI, Kailing LI, Tao ZHANG, Hanzhang WANG, SVATEK, Robert S., RODRIGUEZ, Ronald, and Zhiping WANG
- Published
- 2021
- Full Text
- View/download PDF
38. Small RNA-induced INTS6 gene up-regulation suppresses castration-resistant prostate cancer cells by regulating β-catenin signaling
- Author
-
Liping Xie, Hong Chen, Haixiang Shen, Yeqing Mao, Yiwei Lin, and Ben Liu
- Subjects
0301 basic medicine ,Male ,Ribosomal Proteins ,Transcriptional Activation ,Small RNA ,Time Factors ,Cell Survival ,Genetic enhancement ,Down-Regulation ,RNA activation ,Biology ,Epigenesis, Genetic ,03 medical and health sciences ,Downregulation and upregulation ,Cell Movement ,Cell Line, Tumor ,Humans ,Promoter Regions, Genetic ,Molecular Biology ,Gene ,Wnt Signaling Pathway ,beta Catenin ,Aged ,RNA, Double-Stranded ,Regulation of gene expression ,Base Sequence ,Tumor Suppressor Proteins ,Wnt signaling pathway ,RNA-Binding Proteins ,Epithelial Cells ,Cell Biology ,Cell Cycle Checkpoints ,Clone Cells ,Up-Regulation ,Gene Expression Regulation, Neoplastic ,Prostatic Neoplasms, Castration-Resistant ,030104 developmental biology ,Cancer research ,INTS6 Gene ,Developmental Biology ,Research Paper - Abstract
Small RNAs play an important role in gene regulatory networks. The gene suppressive effect of small RNAs was previously the dominant focus of studies, but during the recent decade, small RNA-induced gene activation has been reported and has become a notable gene manipulation technique. In this study, a putative tumor suppressor, INTS6, was activated by introducing a promoter-targeted small RNA (dsRNA-915) into castration-resistant prostate cancer (CRPC) cells. Unique dynamics associated with the gene upregulation phenomenon was observed. Following gene activation, cell proliferation and motility were suppressed in vitro. Downregulation of Wnt/β-catenin signaling was observed during the activation period, and the impairment of β-catenin degradation reversed the tumor suppressor effects of INTS6. These results suggest the potential application of small activating RNAs in targeted gene therapy for CRPC.
- Published
- 2018
39. Real-Time Detection of Cook Assistant Overalls Based on Embedded Reasoning
- Author
-
Qinghua Sheng, Haixiang Sheng, Peng Gao, Zhu Li, and Haibing Yin
- Subjects
edge computing ,edge intelligence ,Hi3559 ,overall recognition ,embedded ,Chemical technology ,TP1-1185 - Abstract
Currently, the target detection based on convolutional neural network plays an important role in image recognition, speech recognition and other fields. However, the current network model features a complex structure, a huge number of parameters and resources. These conditions make it difficult to apply in embedded devices with limited computational capabilities and extreme sensitivity to power consumption. In this regard, the application scenarios of deep learning are limited. This paper proposes a real-time detection scheme for cook assistant overalls based on the Hi3559A embedded processor. With YOLOv3 as the benchmark network, this scheme fully mobilizes the hardware acceleration resources through the network model optimization and the parallel processing technology of the processor, and improves the network reasoning speed, so that the embedded device can complete the task of real-time detection on the local device. The experimental results show that through the purposeful cropping, segmentation and in-depth optimization of the neural network according to the specific processor, the neural network can recognize the image accurately. In an application environment where the power consumption is only 5.5 W, the recognition speed of the neural network on the embedded end is increased to about 28 frames (the design requirement was to achieve a recognition speed of 25 frames or more), so that the optimized network can be effectively applied in the back kitchen overalls identification scene.
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.